liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension
Linköping University, Department of Clinical and Experimental Medicine, Ophthalmology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Reconstruction Centre, Department of Ophthalmology UHL/MH.
University of Tampere.
2010 (English)In: ACTA OPHTHALMOLOGICA, ISSN 1755-375X, Vol. 88, no 1, 37-43 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: To compare the effect of time on therapy, efficacy, tolerability and resource utilization of latanoprost or non-prostaglandin analogues (non-PGs) in patients who required a change in intraocular pressure (IOP)-lowering monotherapy. Methods: This open-label, multicentre study (Sweden, 19 sites; Finland, seven sites) included adults with glaucoma or ocular hypertension with mean diurnal IOP andgt;= 21 mmHg on ocular hypotensive monotherapy. Patients were randomized to latanoprost monotherapy or non-PG therapy (commercially available therapy other than a PG) and followed for 36 months. End-points included: time to treatment failure (baseline to visit with a change in/addition to treatment); diurnal IOP (mean of 08.00, 12.00 and 16:00 hr measurements) at months 6, 12, 24 and 36; tolerability; and resource utilization, where analyses used Swedish and Finnish 2006 unit costs. Results: Three hundred and twenty-six patients received andgt;= 1 dose of latanoprost (n = 162) or non-PGs (n = 164). Median time to treatment failure was longer for latanoprost (36 months) than for non-PGs (12 months; p andlt; 0.001); 51% and 24% of patients remained on randomized therapy after 36 months, respectively (p andlt; 0.001). Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p andlt; 0.01). No serious adverse events were judged to be treatment-related. Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs. Conclusion: Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost. Latanoprosts IOP-reducing effect and tolerability were sustained over the long term. Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.

Place, publisher, year, edition, pages
2010. Vol. 88, no 1, 37-43 p.
Keyword [en]
efficacy, glaucoma, health resource utilization, latanoprost, ocular hypertension, persistency, tolerability
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-54086DOI: 10.1111/j.1755-3768.2009.01663.xISI: 000274168900008OAI: diva2:298244
Available from: 2010-02-22 Created: 2010-02-22 Last updated: 2010-02-22

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Friström, Björn
By organisation
Ophthalmology Faculty of Health SciencesDepartment of Ophthalmology UHL/MH
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 20 hits
ReferencesLink to record
Permanent link

Direct link